Payment overview · 2025
General Payments
$287.75
32 reported records · 7 companies
Healthcare provider profile · identity verified
Michael D Woolery, MD
Allopathic & Osteopathic Physicians|Family Medicine · ZANESVILLE, OH · NPI 1881699114
Verified facts
What the public records show
CMS Open Payments records show Michael D Woolery, MD received $287.75 in general payments during 2025 across 32 reported records.
ABBVIE INC. accounted for 48.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $139.90 | 48.6% | 17 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.96 | 14.6% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $36.32 | 12.6% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $23.84 | 8.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.23 | 6.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.83 | 5.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.67 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $287.75 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $139.90 | 17 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $92.99 | 12 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $41.96 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $36.32 | 2 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 607 | 89 |
| Gabapentin | Gabapentin | 598 | 118 |
| Lisinopril | Lisinopril | 583 | 150 |
| Levothyroxine Sodium | Levothyroxine Sodium | 528 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 526 | 130 |
| Pantoprazole Sodium | Pantoprazole Sodium | 420 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 412 | 112 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 351 | 50 |
| Omeprazole | Omeprazole | 333 | 97 |
| Atorvastatin Calcium | Atorvastatin Calcium | 323 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 316 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 273 | 90 |
| Losartan Potassium | Losartan Potassium | 266 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 264 | 66 |
| Tramadol Hcl | Tramadol Hcl | 263 | 46 |
| Metformin Hcl | Metformin Hcl | 245 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 233 | 60 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 232 | 55 |
| Glipizide Er | Glipizide | 226 | 59 |
| Furosemide | Furosemide | 222 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 220 | 68 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 219 | 25 |
| Bupropion Xl | Bupropion Hcl | 215 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 211 | 50 |
| Simvastatin | Simvastatin | 179 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 47 |
| Potassium Chloride | Potassium Chloride | 150 | 38 |
| Sertraline Hcl | Sertraline Hcl | 149 | 29 |
| Prednisone | Prednisone | 147 | 73 |
| Diclofenac Sodium | Diclofenac Sodium | 143 | 32 |
| Spironolactone | Spironolactone | 142 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 139 | 30 |
| Propranolol Hcl Er | Propranolol Hcl | 131 | 31 |
| Allopurinol | Allopurinol | 129 | 36 |
| Metformin Hcl Er | Metformin Hcl | 129 | 33 |
| Atenolol | Atenolol | 113 | 31 |
| Carvedilol | Carvedilol | 110 | 29 |
| Eliquis | Apixaban | 109 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 36 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 105 | 54 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 102 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 101 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 100 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 92 | 21 |
| Warfarin Sodium | Warfarin Sodium | 92 | 16 |
| Meloxicam | Meloxicam | 89 | 25 |
| Ondansetron Odt | Ondansetron | 87 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 23 |
| Cefdinir | Cefdinir | 81 | 67 |
| Amitriptyline Hcl | Amitriptyline Hcl | 80 | 21 |
| Farxiga | Dapagliflozin Propanediol | 80 | 17 |
| Jardiance | Empagliflozin | 79 | 17 |
| Ozempic | Semaglutide | 78 | 15 |
| Methadone Hcl | Methadone Hcl | 77 | 11 |
| Trazodone Hcl | Trazodone Hcl | 77 | 21 |
| Alendronate Sodium | Alendronate Sodium | 76 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 74 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 21 |
| Glimepiride | Glimepiride | 72 | 21 |
| Ibuprofen | Ibuprofen | 72 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 52 |
| Lorazepam | Lorazepam | 65 | 17 |
| Trulicity | Dulaglutide | 65 | 13 |
| Ezetimibe | Ezetimibe | 62 | 21 |
| Finasteride | Finasteride | 62 | 18 |
| Xarelto | Rivaroxaban | 62 | 13 |
| Synthroid | Levothyroxine Sodium | 61 | 15 |
| Buspirone Hcl | Buspirone Hcl | 60 | 16 |
| Montelukast Sodium | Montelukast Sodium | 57 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | suppressed |
| Nabumetone | Nabumetone | 49 | 13 |
| Methotrexate | Methotrexate Sodium | 48 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 47 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 46 | 19 |
| Nystatin | Nystatin | 46 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | 13 |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Celecoxib | Celecoxib | 41 | 12 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Primidone | Primidone | 38 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 38 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Etodolac | Etodolac | 35 | 12 |
| Fenofibrate | Fenofibrate,micronized | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 31 |
| Lovastatin | Lovastatin | 33 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | 12 |
| Levofloxacin | Levofloxacin | 32 | 26 |
| Tradjenta | Linagliptin | 32 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 31 | suppressed |
| Famotidine | Famotidine | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 18 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 20 |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Naproxen | Naproxen | 24 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 15 |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 18 |
| Dilt-Xr | Diltiazem Hcl | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | 12 |
| Nitroglycerin | Nitroglycerin | 19 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Risperidone | Risperidone | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 12 |
| Torsemide | Torsemide | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Pregabalin Er | Pregabalin | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $287.75 · 32 records | ABBVIE INC. | AIRSUPRA, CAPLYTA, Dexcom G6 Transmitter, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), GEMTESA, QULIPTA, UBRELVY, VOQUEZNA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error